Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $10

Benzinga Newsdesk 16 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $15 to $10.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $15 to $10.

Read at benzinga.com